Company intelligence / Profile preview

Aleta Biotherapeutics

Natick, Massachusetts, United Statesaletabio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Aleta’s lead asset ALETA‑001 is in a Phase 1/2 trial for patients relapsed/refractory to CD19-targeting CAR T therapy. The company’s CTEs are designed to enhance the efficacy of existing CAR T therapies by increasing target antigen density and overcoming resistance. Early clinical data and preclinical results suggest potential to improve response rates in high unmet need populations such as relapsed B-cell malignancies and multiple myeloma. Clinical trials began in February 2024 and are ongoing; no published efficacy results yet.

Therapeutic areas: Oncology
Modalities: Biologics (CAR T Engagers/CTEs)Cell therapies (CAR T-cell therapy)
Industry: Biotech

Drug pipeline

6 assets

ALETA-001

5 more assets in the full pipeline.

Request access →

Partnerships

Cancer Research UK Centre for Drug Development – major collaborator/funder on ALETA–001 clinical trials

Beyond the preview

Go deeper on Aleta Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aleta Biotherapeutics.

Explore the full profile